BNTX
Income statement / Annual
Last year (2024), BioNTech SE's total revenue was $2.75 B,
a decrease of 27.96% from the previous year.
In 2024, BioNTech SE's net income was -$665.30 M.
See BioNTech SE,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$2.75 B |
$3.82 B |
$17.31 B |
$18.98 B |
$482.33 M |
$108.59 M |
$127.58 M |
$61.60 M |
| Cost of Revenue |
$541.30 M
|
$599.80 M
|
$4.53 B
|
$3.86 B
|
$704.36 M
|
$243.83 M
|
$156.73 M
|
$94.81 M
|
| Gross Profit |
$2.21 B
|
$3.22 B
|
$12.78 B
|
$15.12 B
|
-$222.04 M
|
-$135.24 M
|
-$29.16 M
|
-$33.22 M
|
| Gross Profit Ratio |
0.8
|
0.84
|
0.74
|
0.8
|
-0.46
|
-1.25
|
-0.23
|
-0.54
|
| Research and Development Expenses |
$2.25 B
|
$1.78 B
|
$1.46 B
|
$952.85 M
|
$645.03 M
|
$226.47 M
|
$143.04 M
|
$85.50 M
|
| General & Administrative Expenses |
$531.10 M
|
$495.00 M
|
$484.70 M
|
$278.50 M
|
$94.05 M
|
$40.69 M
|
$24.05 M
|
$22.89 M
|
| Selling & Marketing Expenses |
$67.90 M
|
$62.70 M
|
$59.50 M
|
$50.40 M
|
$14.51 M
|
$2.72 M
|
$3.04 M
|
$6.60 M
|
| Selling, General & Administrative Expenses |
$599.00 M
|
$557.70 M
|
$544.20 M
|
$328.90 M
|
$108.56 M
|
$43.41 M
|
$27.09 M
|
$29.49 M
|
| Other Expenses |
$670.90 M
|
$188.00 M
|
-$408.30 M
|
-$128.80 M
|
-$893.21 M
|
-$223.60 M
|
-$145.43 M
|
-$86.93 M
|
| Operating Expenses |
$3.52 B
|
$2.53 B
|
$135.90 M
|
$200.10 M
|
-$139.62 M
|
$46.28 M
|
$24.70 M
|
$28.06 M
|
| Cost And Expenses |
$4.07 B
|
$3.13 B
|
$4.67 B
|
$4.06 B
|
$564.74 M
|
$290.11 M
|
$181.43 M
|
$122.88 M
|
| Interest Income |
$437.60 M
|
$350.27 M
|
$330.30 M
|
$1.50 M
|
$1.56 M
|
$1.78 M
|
$2.00 M
|
$2.13 M
|
| Interest Expense |
$12.60 M
|
$569,936.00
|
$18.90 M
|
$5.40 M
|
$64.95 M
|
$1.72 M
|
$1.72 M
|
$676,000.00
|
| Depreciation & Amortization |
$298.00 M
|
$183.40 M
|
$121.08 M
|
$78.20 M
|
$36.10 M
|
$33.80 M
|
$22.69 M
|
$9.85 M
|
| EBITDA |
-$367.10 M |
$1.09 B |
$12.86 B |
$15.73 B |
-$97.89 M |
-$143.41 M |
-$24.64 M |
-$70.13 M |
| EBITDA Ratio |
-0.13
|
0.28
|
0.74
|
0.79
|
-0.09
|
-1.35
|
-0.24
|
-0.79
|
| Operating Income Ratio |
-0.48
|
0.18
|
0.73
|
0.81
|
-0.17
|
-1.67
|
-0.42
|
-0.99
|
| Total Other Income/Expenses Net |
$636.60 M
|
$495.70 M
|
$311.40 M
|
-$237.40 M
|
-$63.40 M
|
$2.10 M
|
$6.19 M
|
-$24.63 M
|
| Income Before Tax |
-$677.70 M
|
$1.19 B
|
$12.95 B
|
$15.05 B
|
-$145.80 M
|
-$179.44 M
|
-$47.66 M
|
-$85.91 M
|
| Income Before Tax Ratio |
-0.25
|
0.31
|
0.75
|
0.79
|
-0.3
|
-1.65
|
-0.37
|
-1.39
|
| Income Tax Expense |
-$12.40 M
|
$255.80 M
|
$3.52 B
|
$4.75 B
|
-$161.00 M
|
-$268,000.00
|
$600,000.00
|
$45,000.00
|
| Net Income |
-$665.30 M
|
$930.30 M
|
$9.43 B
|
$10.29 B
|
$15.20 M
|
-$179.17 M
|
-$48.02 M
|
-$85.65 M
|
| Net Income Ratio |
-0.24
|
0.24
|
0.55
|
0.54
|
0.03
|
-1.65
|
-0.38
|
-1.39
|
| EPS |
-2.77 |
3.87 |
38.08 |
43.87 |
0.0602 |
-0.85 |
-0.21 |
-0.38 |
| EPS Diluted |
-2.77 |
3.83 |
37.09 |
41.21 |
0.057 |
-0.85 |
-0.21 |
-0.38 |
| Weighted Average Shares Out |
$240.40 M
|
$240.60 M
|
$243.30 M
|
$244.00 M
|
$235.44 M
|
$211.50 M
|
$226.86 M
|
$226.86 M
|
| Weighted Average Shares Out Diluted |
$240.40 M
|
$242.70 M
|
$249.80 M
|
$259.70 M
|
$248.53 M
|
$211.50 M
|
$226.86 M
|
$226.86 M
|
| Link |
|
|
|
|
|
|
|
|
